Spruce Biosciences, Inc. (SPRB)
| Market Cap | 133.72M +4,734.2% |
| Revenue (ttm) | n/a |
| Net Income | -37.19M |
| EPS | -38.62 |
| Shares Out | 2.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,471 |
| Open | 48.92 |
| Previous Close | 49.19 |
| Day's Range | 47.49 - 50.22 |
| 52-Week Range | 4.35 - 240.00 |
| Beta | 3.31 |
| Analysts | Strong Buy |
| Price Target | 168.00 (+239.5%) |
| Earnings Date | May 13, 2026 |
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sle... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SPRB stock is "Strong Buy." The 12-month stock price target is $168.0, which is an increase of 239.50% from the latest price.
News
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences to Participate in Upcoming Conferences in June
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Transcript: AGM 2026
The meeting confirmed quorum, elected three directors, and approved all proposals, including auditor ratification and annual say-on-pay votes. Management addressed financing, manufacturing, and clinical trial plans, with key milestones aligned with FDA guidance.
Spruce Biosciences price target lowered to $150 from $170 at Citizens
Citizens lowered the firm’s price target on Spruce Biosciences (SPRB) to $150 from $170 and keeps an Outperform rating on the shares. Spruce remains on track to submit its TA-ERT…
Spruce Biosciences reports Q1 EPS ($8.94), consensus ($6.11)
“We are very pleased with the meaningful progress we continue to make in advancing TA-ERT toward our planned biologics license application submission in the fourth quarter of 2026. This would…
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Earnings release: Q1 2026
Spruce Biosciences released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Spruce Biosciences Quarterly report: Q1 2026
Spruce Biosciences has published its Q1 2026 quarterly earnings report on May 13, 2026.
Spruce Biosciences appoints Brian Walls as VP, market access
Spruce Biosciences (SPRB) announced the appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations. Most recently, Walls served as Vice Pr...
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy
AS previously reported, Craig-Hallum initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $140 price target. The firm notes the company’s TA-ERT is an enzyme replacement therapy for…
Spruce Biosciences initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Albert Lowe initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $140 price target
Spruce Biosciences 1.15M share Spot Secondary priced at $50.00
Leerink, Guggenheim and Oppenheimer acted as joint book running managers for the offering.
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel the...
Spruce Biosciences down 13% at $60.50 after equity offering announcement
16:48 EDT Spruce Biosciences (SPRB) down 13% at $60.50 after equity offering announcement
Spruce Biosciences announces common stock offering, no amount given
Spruce Biosciences (SPRB) announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu…
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel the...
Spruce Biosciences Proxy statement: Proxy filing
Spruce Biosciences filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Spruce Biosciences Proxy statement: Proxy filing
Spruce Biosciences filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026
Lead asset for MPS IIIB shows robust clinical benefit and safety, with regulatory progress supported by FDA engagement and a Q4 BLA submission planned. Commercial strategy targets a rare disease market with strong patient advocacy, and financial runway extends into 2027.
Spruce Biosciences price target lowered to $170 from $180 at Citizens
Citizens lowered the firm’s price target on Spruce Biosciences (SPRB) to $170 from $180 and keeps an Outperform rating on the shares. The firm continues to like Tralesinidase Alfa Enzyme…
Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026
FDA engagement has been positive, supporting accelerated approval based on robust biomarker and clinical data, with BLA submission planned for Q4. Commercial and manufacturing strategies are advancing, and financial runway is expected into 2027, with additional funding options available.
Spruce Biosciences appoints Dale Hooks as chief commercial officer
Spruce Biosciences (SPRB) announced the appointment of Dale Hooks as chief commercial officer. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including ...
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...